Objective: This post-hoc analysis evaluated the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson’s disease (PD) treated in real-world conditions.
Background: OPC proved to be effective in treating end-of-dose motor fluctuations (MF) in patients with PD [1,2]. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of patients treated in real-world conditions [3].
Method: OPTIPARK was a prospective, open-label, single-arm trial conducted in Germany and the UK. Patients with MF received OPC 50 mg in addition to current antiparkinsonian treatment. The primary efficacy 3-month endpoint was Clinician’s-Global-Impression-of-Change (CGI-C). Secondary efficacy endpoints included Patient’s-CGI-C (PGI-C), 8-item PD-Questionnaire (PDQ-8), Unified PD Rating Scale (UPDRS), and Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). This post-hoc analysis evaluated the influence of OMF at baseline in patients who completed the study for each outcome.
Results: Overall, 393 (82.4%) patients completed the 3-month endpoint (completers-set, Table 1). Of these, although somehow similar, patients with higher OMF reported greater improvements’ perception on CGI-C and PGI-C, when compared with recent fluctuators’ patients (≤1 year OMF) (Table 2). However, recent fluctuators experienced greater improvements on UPDRS-II, quality-of-life (PDQ-8), and non-motor symptoms (NMSS) – no difference was observed for UPDRS-III – (Table 3). Furthermore, lower incidence of TEAEs considered at least possibly related to OPC were also reported for recent fluctuators (Table 3).
Conclusion: Overall, these findings indicate that recent fluctuators may benefit at least as much as patients with higher OMF from using OPC 50 mg as adjunctive therapy to levodopa.
References: 1. Ferreira et al., Lancet Neurology 2016; 15(2):154-165. 2. Lees et al., JAMA Neurol. 2017; 74(2):197-206. 3. Reichmann et al., Transl Neurodegener. 2020;9(1):9
To cite this abstract in AMA style:
W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva. Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/influence-of-onset-of-motor-fluctuations-on-the-effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-findings-from-the-real-world-optipark-study/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/influence-of-onset-of-motor-fluctuations-on-the-effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-findings-from-the-real-world-optipark-study/